Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 922M 811M 767M 696M 1.31B 88.51B 1.31B 9.18B 3.55B 45.16B 3.46B 3.39B 145B P/E 2026 *
15.7x
P/E 2027 * 12.7x
Enterprise Value 922M 811M 767M 696M 1.31B 88.51B 1.31B 9.18B 3.55B 45.16B 3.46B 3.39B 145B EV / Sales 2026 *
3.02x
EV / Sales 2027 * 2.47x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+2.45%
1 week+4.82%
Current month+6.89%
1 month+6.20%
3 months+27.58%
6 months+91.24%
Current year+15.25%
1 week 46.91
Extreme 46.9101
49.64
1 month 43.78
Extreme 43.78
49.9
Current year 24.95
Extreme 24.95
49.9
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Exercice

Chief Financial Officer

9,200 0.0493%
9/1/26 Tax

Compliance Officer

-877 0.0047%
9/1/26 Tax

Chief Executive Officer

-2,424 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%+4.82%+72.41%+340.71% 900M
+0.11%+1.71%+63.52%+117.61% 1,055B
+0.27%+0.92%+51.33%+73.35% 654B
+0.73%+0.68%+20.70%+74.90% 467B
-1.36%-2.58%+40.20%+42.33% 348B
+1.34%+4.53%+23.37%+29.55% 275B
-0.48%-0.54%+13.56%+13.50% 258B
+0.85%+6.35%+53.17%+54.39% 224B
+0.85%+1.10%+35.78%+101.82% 187B
-0.30%-2.98%-27.62%-61.28% 171B
Average +0.36%+0.95%+34.64%+78.69% 363.92B
Weighted average by Cap. -0.05%+1.00%+40.70%+69.91%

Financials

2026 *2027 *
Net sales 306M 269M 254M 231M 433M 29.35B 436M 3.04B 1.18B 14.98B 1.15B 1.12B 48.12B 373M 328M 310M 281M 528M 35.79B 531M 3.71B 1.43B 18.26B 1.4B 1.37B 58.69B
Net income 61.66M 54.23M 51.28M 46.51M 87.35M 5.92B 87.86M 614M 237M 3.02B 231M 226M 9.71B 81.45M 71.63M 67.74M 61.44M 115M 7.82B 116M 811M 313M 3.99B 306M 299M 12.82B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-09-28 US$49.36 +2.45% 180,868
26-09-25 US$48.18 +0.61% 204,930
26-09-24 US$47.89 -0.50% 143,824
26-09-23 US$48.13 -1.41% 151,375
26-09-22 US$48.82 +3.67% 242,877
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
49.36USD
Average target price
63.00USD
Spread / Average Target
+27.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock